Clindamycin treats a wide range of bacterial infections, with particular strength against skin and soft tissue infections, bone and joint infections, respiratory infections, pelvic infections, and infections caused by anaerobic bacteria (the kind that thrive without oxygen). It works by stopping bacteria from building the proteins they need to grow and multiply, binding to a specific part of the bacterial ribosome to shut down protein production.
Skin and Soft Tissue Infections
Skin infections are one of the most common reasons clindamycin is prescribed. It covers a broad range of skin problems caused by staph and strep bacteria, including cellulitis, folliculitis, boils, abscesses, impetigo, and wound infections. It also plays a role in treating deeper, more dangerous soft tissue infections like necrotizing fasciitis (sometimes called “flesh-eating” infection) and infected diabetic foot ulcers, typically as part of a multi-drug combination.
Clindamycin is especially useful for community-acquired MRSA, a drug-resistant staph infection that doesn’t respond to many standard antibiotics. In areas where MRSA is common, clindamycin is one of the go-to oral options for skin infections. That said, for drainable abscesses, physically draining the pus is the most important step. No antibiotic works well if an infected collection isn’t properly drained first.
Acne and Topical Uses
In dermatology, clindamycin is most widely used as a topical gel, lotion, or solution for acne. Applied directly to the skin, it kills acne-causing bacteria without exposing the whole body to the drug. It’s available on its own or combined with other acne-fighting ingredients like benzoyl peroxide, tretinoin, or adapalene. Topical clindamycin is also sometimes used off-label for conditions like rosacea, perioral dermatitis, and hidradenitis suppurativa.
Oral clindamycin for acne has become less common in recent years, partly because of concerns about antibiotic resistance and the gut-related side effects that come with systemic use.
Respiratory Infections
Clindamycin is FDA-approved for serious respiratory tract infections caused by staph, strep, pneumococcus, and anaerobic bacteria. This includes lung abscesses, anaerobic pneumonia, and empyema (a collection of pus between the lung and chest wall). These are typically infections where anaerobic bacteria play a significant role, and clindamycin’s strong activity against anaerobes makes it particularly valuable.
One important distinction: clindamycin’s FDA label specifically warns against using it for most upper respiratory infections. Common colds, sinus infections, and sore throats are usually viral and don’t need antibiotics at all. Clindamycin is meant for serious bacterial infections where milder alternatives aren’t appropriate.
Bone and Joint Infections
Clindamycin penetrates bone tissue well, which makes it useful for osteomyelitis (bone infection) and septic arthritis. These infections often involve staph bacteria, and clindamycin’s ability to reach adequate concentrations in bone gives it an advantage over antibiotics that don’t distribute as effectively into hard tissue. It’s frequently used when a patient can’t tolerate penicillin-type drugs or when MRSA is involved.
Pelvic and Abdominal Infections
Clindamycin is a standard part of treatment for several types of pelvic and abdominal infections where anaerobic bacteria are involved. The CDC includes it in treatment guidelines for pelvic inflammatory disease as part of a combination regimen. For tubo-ovarian abscesses, clindamycin provides the anaerobic coverage that other antibiotics in the regimen may lack.
It’s also approved for intra-abdominal infections like peritonitis and abdominal abscesses, which typically arise when gut bacteria escape into the abdominal cavity after surgery, injury, or a ruptured appendix. These infections almost always involve a mix of aerobic and anaerobic bacteria, and clindamycin handles the anaerobic side of that equation. Additionally, clindamycin is used to treat bacterial vaginosis, available as either an oral pill or a vaginal cream, and for perinatal infections caused by group B strep.
Penicillin Allergy Alternative
For many of the infections listed above, clindamycin isn’t necessarily the first-line choice. Its FDA labeling notes that for infections caused by strep, staph, and pneumococcus, it should generally be reserved for patients who are allergic to penicillin or who can’t take penicillin-type antibiotics for other reasons. This is partly because of the serious gut-related risks that come with clindamycin (more on that below).
Notably, clindamycin is no longer recommended for preventing heart valve infections before dental procedures. It used to be a standard alternative for penicillin-allergic patients, but guidelines changed after data showed clindamycin caused 13 fatal and 149 nonfatal adverse reactions per million prescriptions in that setting, compared to zero fatal reactions for amoxicillin. Most of those serious reactions were tied to C. difficile infection.
Why Resistance Testing Matters
One quirk of clindamycin is that some bacteria can look sensitive to it in standard lab testing but develop resistance during treatment. This happens through a mechanism called inducible resistance, where exposure to related antibiotics (particularly erythromycin) flips a genetic switch that makes the bacteria resistant to clindamycin too. In the lab, this shows up as a flattened, D-shaped zone around the clindamycin test disc when it’s placed near an erythromycin disc.
If your doctor orders a culture and sensitivity test, the lab may perform this “D-test” to check for hidden resistance. A bacteria that tests sensitive to clindamycin but resistant to erythromycin could still fail clindamycin treatment if this inducible resistance is present. This is especially relevant for staph infections, where catching this pattern upfront prevents a course of antibiotics that won’t work.
The C. Difficile Risk
Clindamycin carries a black box warning, the FDA’s most serious safety label, for its association with C. difficile infection. This happens because clindamycin disrupts the normal bacteria in your gut, allowing C. difficile to overgrow and produce toxins that cause severe diarrhea and colon inflammation. In rare cases, this can progress to life-threatening colitis.
C. difficile symptoms can appear during treatment or up to two months after finishing the antibiotic. Any diarrhea that develops during or after a course of clindamycin should be taken seriously. Some strains of C. difficile produce unusually high levels of toxin, making them harder to treat and potentially requiring surgery in the most severe cases. This risk is the main reason clindamycin is reserved for infections serious enough to justify it, rather than being used casually for mild bacterial problems.